Nephroprotective Activity of Papaloquelite (Porophyllum ruderale) in Thioacetamide-Induced Injury Model

Abstract

Acute kidney injury and impaired kidney function is associated with reduced survival and increased morbidity. Porophyllum ruderale is an edible plant endemic to Mexico used in Mexican traditional medicine. The aim of this study was to evaluate the nephroprotective effect of a hydroalcoholic extract (MeOH:water 70:30, v/v) from the aerial parts of P. ruderale (HEPr). Firstly, in vitro the antioxidant and anti-inflammatory activity of HEPr was determined; after the in vivo nephroprotective activity of HEPr was evaluated using a thioacetamide-induced injury model in rats. HEPr showed a slight effect on LPS-NO production in macrophages (15% INO at 40 µg/mL) and high antioxidant activity in the ferric reducing antioxidant power (FRAP) test, followed by the activity on DPPH and ABTS radicals test (69.04, 63.06 and 32.96% of inhibition, respectively). In addition, values of kidney injury biomarkers in urine (urobilinogen, hemoglobin, bilirubin, ketones, glucose, protein, pH, nitrites, leukocytes, specific gravity, and the microalbumin/creatinine) and serum (creatinine, urea, and urea nitrogen) of rats treated with HEPr were maintained in normal ranges. Finally, 5-O-caffeoylquinic, 4-O-caffeoylquinic and ferulic acids; as well as 3-O-quercetin glucoside and 3-O-kaempferol glucoside were identified by HPLC as major components of HEPr. In conclusion, Porophyllum ruderale constitutes a source of compounds for the treatment of acute kidney injury.

SIRT1/Nrf2/NF-κB Signaling Mediates Anti-Inflammatory and Anti-Apoptotic Activities of Oleanolic Acid in a Mouse Model of Acute Hepatorenal Damage

“…TAA is a powerful hepato- and nephrotoxic agent that is widely used to establish a reproducible model of acute liver and kidney injury [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. OA is a penta-cyclic triterpene that exists in free or glycosidic forms with one or more sugar moieties.…”

“…The increase in serum creatinine indicates leakage from necrotic cells or its biosynthesis upregulation. BUN reflects the accumulated urea amount that is not effectively excreted due to kidney impairment [ 5 , 37 ]. In this study, TAA injection affected hepatic and kidney function as presented by elevated levels of serum transaminases, creatinine, and BUN.…”

“…TAA causes toxic injuries in multiple organs such as the brain, kidney, intestine, liver, lung, spleen, and stomach, resulting in functional and structural abnormalities ranging from necrosis, and fibrosis to cirrhosis [ 4 ]. The deleterious effect of TAA depends on its dose and the exposure time; i.e., a single-dose administration produces hepatic injury in the form of apoptosis, centrilobular hepatic necrosis, and peri-portal inflammatory cell infiltration, while long-time exposure leads to liver cirrhosis and bile duct proliferation [ 4 , 5 , 6 ].…”

Preclinical evidence of reno-protective effect of quercetin on acute kidney injury: a meta-analysis of animal studies

“…This meta-analysis included 18 research with 278 animals (Chander et al, 2005;Kusumoto et al, 2011;Sanchez-Gonzalez et al, 2011;Nabavi et al, 2012;Saito et al, 2014;Li et al, 2016;Gholampour and Sadidi, 2018;Shu et al, 2018;Tan et al, 2019;Tan et al, 2020;El-Sayed et al, 2021;Goncalves et al, 2021;Rahdar et al, 2021;Wang et al, 2020;Ali et al, 2022;Vazquez-Atanacio et al, 2022;Yilmaz et al, 2022). The result showed that quercetin administration obviously decreased BUN (SMD = −4.78; 95% CI: 6.45, −3.12; p < 0.01; I 2 = 84%) in AKI animals (Figure 2A).…”

“…After reading the full-text articles, 55 studies were excluded due to 1) the animal model not being correct, 2) data not being clear, 3) duplicate data, and 4) the original text not being available. Finally, 19 studies were eligible in which 288 animals were included (Chander et al, 2005;Kusumoto et al, 2011;Sanchez-Gonzalez et al, 2011;Nabavi et al, 2012;Chen et al, 2014;Saito et al, 2014;Li et al, 2016;Gholampour and Sadidi, 2018;Shu et al, 2018;Lucida et al, 2019;Tan et al, 2019;Tan et al, 2020;El-Sayed et al, 2021;Goncalves et al, 2021;Rahdar et al, 2021;Wang et al, 2020;Ali et al, 2022;Vazquez-Atanacio et al, 2022;Yilmaz et al, 2022) (Figure 1). Frontiers in Pharmacology frontiersin.org Frontiers in Pharmacology frontiersin.org…”